
Title:
Losartan
Text:
Blood pressure medication


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}LosartanClinical dataPronunciation/loʊˈsɑːrtən/ Trade namesCozaar, othersAHFS/Drugs.comMonographMedlinePlusa695008License data
US DailyMed: Losartan
US FDA: Losartan
Pregnancycategory
AU: D[1]

Routes ofadministrationBy mouthDrug classAngiotensin II receptor antagonistATC codeC09CA01 (WHO) Legal statusLegal status
US: ℞-only [2]
In general: ℞ (Prescription only)
Pharmacokinetic dataBioavailability25–35%Protein binding99.7% (primarily albumin)MetabolismLiver (CYP2C9, CYP3A4)Elimination half-life1.5–2 hoursExcretionKidney 13–25%, bile duct 50–60%Identifiers
IUPAC name
(2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
CAS Number114798-26-4 YPubChem CID3961IUPHAR/BPS590DrugBankDB00678 YChemSpider3824 YUNIIJMS50MPO89KEGGD08146 YChEBICHEBI:6541 YChEMBLChEMBL191 YCompTox Dashboard (EPA)DTXSID7023227 ECHA InfoCard100.110.555 Chemical and physical dataFormulaC22H23ClN6OMolar mass422.92 g·mol−13D model (JSmol)Interactive image
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) YKey:PSIFNNKUMBGKDQ-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Losartan, sold under the brand name Cozaar among others, is a medication used to treat high blood pressure (hypertension).[3] It is also used for diabetic kidney disease, heart failure, and left ventricular enlargement.[3] It is taken by mouth.[3] It may be used alone or in addition to other blood pressure medication.[3] Up to six weeks may be required for the full effects to occur.[3]
Common adverse effects include muscle cramps, stuffy nose, cough, high blood potassium and anemia.[3] Severe adverse effects may include angioedema, low blood pressure, and kidney problems.[3] Use during pregnancy may result in harm to the baby.[3][1] Use is not recommended during breastfeeding.[1] It is in the angiotensin receptor blocker family of medication. It works by blocking angiotensin II.[3]
Losartan was patented in 1986, and approved for medical use in the United States in 1995.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[6] In 2019, it was the ninth most commonly prescribed medication in the United States, with more than 51 million prescriptions.[7][8] A version combined with hydrochlorothiazide is available[3] which, in 2019, was the 73rd most commonly prescribed medication in the United States, with more than 10 million prescriptions.[7][9]

Contents

1 Chemistry
2 Medical uses
3 Adverse effects

3.1 Pregnancy
3.2 Overdose
3.3 Interactions
3.4 Contamination


4 Mechanism of action
5 Pharmacokinetics
6 History
7 Research
8 References
9 Further reading
10 External links



Chemistry[edit]
Losartan potassium is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-metahnol monopotassium salt. Its empirical formula is C22H22CIKN6O, and its molecular weight is 461.01. [10]
Losartan is generally marketed as the (basic) potassium salt of the aromatized negatively charged tetrazole, called "losartan potassium".[11] The molecule has an extended biphenyl group with a tetrazole which is being used in place of the carboxylic acid as a bioisostere.[medical citation needed]

Medical uses[edit]
Losartan is used for hypertension, including in people with left ventricular hypertrophy (enlarged heart muscle), and kidney dysfunction among type II diabetics.[2] It may also delay progression of diabetic nephropathy. It is a suitable pharmacological agent for the reduction of renal disease progression in patients with type 2 diabetes, hypertension, and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[12]
Although evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments for most people (due to both efficacy[medical citation needed] and cost), an angiotensin II receptor antagonist such as losartan is recommended as first-line treatment in people under the age of 55 who cannot tolerate an ACE inhibitor.[13] One study demonstrated losartan was superior to atenolol in the primary prevention of adverse cardiovascular events (myocardial infarction or stroke), with a reduction in cardiovascular morbidity and mortality for a comparable reduction in blood pressure. The maximal effects on blood pressure usually occur within 3–6 weeks of starting losartan.[14]

Adverse effects[edit]
The most common adverse effects for losartan in adults are upper respiratory infections, dizziness, and back pain.[2] People with type 2 diabetes and kidney disease may experience diarrhea, fatigue, low blood pressure, low blood glucose, elevated potassium, chest pain, or allergic reaction.[2] Losartan should not be taken by people who are diabetic and taking aliskiren.[2] Anemia may occur, due to inhibition of the renin–angiotensin system.[15] As with other angiotensin receptor blockers, losartan may injure the liver, although this effect appears to be rare.[16] Electrolyte imbalances may occur in people with kidney problems who take losartan.[2] Adverse outcomes do not differ by sex, age or race.[2]

Pregnancy[edit]
In October 2014, the U.S. Food and Drug Administration (FDA) issued a black box warning that losartan can cause fetal toxicity, and should be discontinued as soon as pregnancy is detected.[17][2] Using losartan while pregnant could result in fetal injury or death.[17][2]

Overdose[edit]
Overdosing would most likely result in decreased blood pressure, which could manifest as an increased heart rate, dizziness, feeling light headed, or loss of consciousness. Mice studies showed that lethality occurred at about 44 to 170 times the maximum recommended dose after the mice weights were taken into account.[2]

Interactions[edit]
Losartan may have adverse interactions with phenobarbital, rifampin, or fluconazole, possibly inhibiting its blood pressure-lowering effects.[2]

Contamination[edit]
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}See also: Valsartan § recalls, and Angiotensin II receptor blocker § recalls
Between November 2018 and September 2019, the FDA announced multiple recalls of tablets containing losartan by Sandoz, Torrent Pharmaceuticals, Hetero Labs, Camber Pharmaceuticals, Legacy Pharmaceutical Packaging, Teva Pharmaceuticals, Vivimed Life Sciences, and Macleods Pharmaceutical Limited due to detection of one of the possible carcinogens N-nitrosodiethylamine, N-methylnitrosobutyric acid, or N-nitroso-N-methyl-4-aminobutyric acid in the active pharmaceutical ingredient (API).[18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]

Mechanism of action[edit]
  Renin-angiotensin-aldosterone system (RAAS)
Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist, reducing the end organ responses to angiotensin II. Losartan administration results in a decrease in total peripheral resistance (afterload) and cardiac venous return (preload). All of the physiological effects of angiotensin II, including release of aldosterone, are antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the status of the renin–angiotensin system. As a result of losartan dosing, plasma renin activity increases due to removal of the angiotensin II feedback. Renin is released from the kidneys when there is reduced renal arterial pressure, sympathetic activation, or increased sodium delivery to the distal renal tubule.[36] Renin then acts by converting angiotensinogen to angiotensin I; angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II; angiotensin II causes vasoconstriction and aldosterone release.[36] Aldosterone serves to retain sodium from the distal renal tubule. Sodium retention ultimately results in increased blood pressure.[37] Therefore, the use of angiotensin II receptor antagonists like losartan result in blocking the downstream effect of renin, angiotensin II, and ultimately decreasing blood pressure.
Angiotensin II receptor antagonists include losartan, valsartan, azilsartan, candesartan, eprosartan, irbesartan, olmesartan, and telmisartan. They all have the same mechanism of action and potentially inhibit the actions of angiotensin better than ACE inhibitors, such as lisinopril, because there are other enzymes than ACE that have the capability of producing angiotensin II.[36]
Losartan is a uricosuric. As a specific inhibitor of the urate transporter 1 (SLC22A12, URAT1), losartan blocks the uptake of uric acid into cells, thus leaving more available in the bloodstream to be filtered and excreted by the kidneys.[38] Because losartan can cause hyperkalemia, individuals should not use potassium supplements or salt substitutes containing potassium without appropriate monitoring by a physician.[39]

Pharmacokinetics[edit]
Losartan is well absorbed following oral administration and undergoes significant first-pass metabolism to produce the 5-carboxylic acid metabolite, designated as EXP3174. About 14% of an oral dosage is converted to this metabolite, which is long-acting (6 to 8 hr) and a noncompetitive antagonist at the AT1 receptor, contributing to the pharmacological effects of losartan. EXP3174 is 10-40 times more potent in blocking AT1 receptors than losartan. In addition, the binding to the target enzyme is pH-sensitive, and the negatively-charged tetrazole ring, which is similar in size to the negative carboxylic acid derivative, may contribute to the activity of the drug.[40]
Losartan's bioavailability is about 33%.[medical citation needed]
Metabolism is primarily by cytochrome P450 isoenzymes CYP2C9 and CYP3A4.[medical citation needed] Peak plasma concentrations of losartan and EXP3174 occur about one hour and three to four hours, respectively, after an oral dose.[medical citation needed] Both losartan and EXP3174 are more than 98% bound to plasma proteins.[medical citation needed] Losartan is excreted in the urine, and in the feces via bile, as unchanged drug and metabolites.[medical citation needed] About 4% of an oral dose is excreted unchanged in urine, and about 6% is excreted in urine as the active metabolite.[medical citation needed] The terminal elimination half lives of losartan and EXP3174 are about 1.5 to 2.5 hours and 3 to 9 hours, respectively.[medical citation needed]
Losartan and other angiotensin-receptor antagonists exhibit fetal toxicity and should be avoided during pregnancy, particularly in the second and third trimesters.[41]

History[edit]
Discovery and development of angiotensin receptor blockers
Research[edit]
See also: Coronavirus disease 2019 § Research, and COVID-19 drug repurposing research
A hypothesis emerged, in an opinion commentary published in March 2020, that AT1R blockers such as losartan may work to mitigate the symptoms of COVID-19 (SARS-CoV-2) infection.[42] Competing hypotheses are that it will make the symptoms worse.[43][44] A study of this question was started in March 2020.[45]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b c .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Losartan (Cozaar) Use During Pregnancy". Drugs.com. Retrieved 10 December 2017.

^ Jump up to: a b c d e f g h i j k "Cozaar- losartan potassium tablet, film coated". DailyMed. 14 November 2019. Retrieved 20 March 2020.

^ Jump up to: a b c d e f g h i j k "Losartan Potassium". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.

^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 470. ISBN 9783527607495.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 127. ISBN 9780857111562.

^ Jump up to: a b "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Losartan - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "Hydrochlorothiazide; Losartan - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "Pharmaceutical formulation of losartan".

^ see negatively charged tetrazole structure

^ Boersma C, Atthobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ (2006). "Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making". PharmacoEconomics. 24 (6): 523–35. doi:10.2165/00019053-200624060-00001. PMID 16761901. S2CID 22960961.

^ "Hypertension in adults: diagnosis and management". National Institute for Health and Care Excellence (NICE). Retrieved 8 April 2017.

^ Abrams A (2007). 'Clinical Drug Therapy Rationales for Nursing Practice. Philadelphia, Pa.: Lippincott Williams & Wilkins. p. 846. ISBN 978-0-7817-6263-2.

^ Cheungpasitporn, W; Thongprayoon, C; Chiasakul, T; Korpaisarn, S; Erickson, SB (November 2015). "Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis". QJM: Monthly Journal of the Association of Physicians. 108 (11): 879–84. doi:10.1093/qjmed/hcv049. PMID 25697787.

^ Patti R, Sinha A, Sharma S, Yoon TS, Kupfer Y (May 2019). "Losartan-induced severe hepatic injury: A case report and literature review". Cureus. 11 (5): e4769. doi:10.7759/cureus.4769. PMC 6663042. PMID 31363450.

^ Jump up to: a b "Cozaar (losartan potassium) 25 mg, 50 mg, and 100 mg Tablets". U.S. Food and Drug Administration (FDA). 16 October 2014. Archived from the original on 12 January 2017. Retrieved 21 July 2015.

^ "FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall" (Press release). U.S. Food and Drug Administration (FDA). 3 October 2019. Archived from the original on 3 October 2019. Retrieved 3 October 2019.

^ "Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 8 November 2018. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". U.S. Food and Drug Administration (FDA). 20 December 2018. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". U.S. Food and Drug Administration (FDA). 3 January 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration (FDA). 22 January 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Updated: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium /Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration (FDA). 1 March 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration (FDA). 18 April 2019. Archived from the original on 6 October 2019. Retrieved 5 October 2019.

^ "Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 6 October 2019. Retrieved 23 September 2019.

^ "Legacy Pharmaceutical Packaging, LLC Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity Found in the Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 15 July 2019. Archived from the original on 13 September 2019. Retrieved 5 October 2019.

^ "Macleods Pharmaceutical Limited Issues Voluntary Nationwide Consumer Level Recall of Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg due to detection of NMBA (N-Nitroso-N-Methyl-4-aminobutyric acid) Impurity". U.S. Food and Drug Administration (FDA). 26 June 2019. Archived from the original on 1 October 2019. Retrieved 5 October 2019.

^ "Teva Pharmaceuticals USA, Inc. Expands Voluntary Nationwide Recall of Losartan Potassium to 50 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply, Inc". U.S. Food and Drug Administration (FDA). 11 June 2019. Archived from the original on 13 September 2019. Retrieved 5 October 2019.

^ "Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity". U.S. Food and Drug Administration (FDA). 3 May 2019. Archived from the original on 13 September 2019. Retrieved 5 October 2019.

^ "Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply". U.S. Food and Drug Administration (FDA). 26 April 2019. Archived from the original on 13 September 2019. Retrieved 5 October 2019.

^ "Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 19 March 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, and 100mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in the Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 28 March 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 15 March 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)". U.S. Food and Drug Administration (FDA). 28 February 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ "Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity". U.S. Food and Drug Administration (FDA). 22 February 2019. Archived from the original on 7 September 2019. Retrieved 5 October 2019.

^ Jump up to: a b c Katzung, Bertram G., editor (30 November 2017). Basic & clinical pharmacology. ISBN 9781259641152. OCLC 1048625746. {{cite book}}: |last= has generic name (help)CS1 maint: multiple names: authors list (link)

^ Graudal, Niels A.; Hubeck-Graudal, Thorbjørn; Jürgens, Gesche (January 2012). "Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review)". American Journal of Hypertension. 25 (1): 1–15. doi:10.1038/ajh.2011.210. ISSN 1941-7225. PMID 22068710.

^ Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K,  et al. (1 October 2008). "Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients". American Journal of Hypertension. 21 (10): 1157–1162. doi:10.1038/ajh.2008.245. PMID 18670416.

^ RxList. The Internet Drug Index. Clinical pharmacology of Cozaar. Retrieved 6 January 2014.

^ Binding of losartan

^ Sica DA, Gehr TW, Ghosh S (2005). "Clinical pharmacokinetics of losartan". Clin Pharmacokinet. 44 (8): 797–814. doi:10.2165/00003088-200544080-00003. PMID 16029066. S2CID 41326620.

^ Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research. 81 (5): 537–540. doi:10.1002/ddr.21656. ISSN 1098-2299. PMC 7228359. PMID 32129518.

^ Watkins, John (28 February 2020). "Preventing a covid-19 pandemic". BMJ. 368: m810. doi:10.1136/bmj.m810. ISSN 1756-1833. PMID 32111649.

^ Kickbusch, Ilona; Leung, Gabriel (31 January 2020). "Response to the emerging novel coronavirus outbreak". BMJ. 368: m406. doi:10.1136/bmj.m406. ISSN 1756-1833. PMID 32005675.

^ "Losartan for Patients With COVID-19 Requiring Hospitalization". ClinicalTrials.gov. 17 March 2020. Retrieved 23 March 2020.


Further reading[edit]
Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA (2015). "Losartan: Comprehensive Profile". Profiles Drug Subst Excip Relat Methodol. 40: 159–94. doi:10.1016/bs.podrm.2015.02.003. PMID 26051686.
Sica DA, Gehr TW, Ghosh S (2005). "Clinical pharmacokinetics of losartan". Clin Pharmacokinet. 44 (8): 797–814. doi:10.2165/00003088-200544080-00003. PMID 16029066. S2CID 41326620.
External links[edit]
"Losartan". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteMerck & Co., Inc.Corporate directors:
Richard Clark
Johnnetta Cole
William Harrison
William Kelley
Rochelle Lazarus
Thomas Shenk
Anne Tatlock
Samuel Thier
Wendell Weeks
Peter Wendell
Subsidiaries:
Acceleron Pharma
Cubist Pharmaceuticals
H. K. Mulford Company
Schering-Plough
Viralytics
Products:
Alendronate
Aprepitant
Ertapenem
Ezetimibe
Ezetimibe/simvastatin
Finasteride
Fosaprepitant
Indinavir
Losartan
Lovastatin
Montelukast
Omarigliptin
Raltegravir
Rizatriptan
Rofecoxib
rVSV-ZEBOV vaccine
Simvastatin
Sitagliptin
Vericiguat
Vorinostat
Schering-Plough:
Coppertone sign
Desloratadine
Ezetimibe
Ezetimibe/simvastatin
Famciclovir
Infliximab
Loratadine
Mometasone
Rocuronium bromide
Temozolomide
Tibolone
Urofollitropin

Facilities:
Merck Headquarters Building
Publications:
Merck Manual of Diagnosis and Therapy
The Merck Manuals
Index
Manual
Veterinary
Geriatrics

vteAntihypertensive drugs acting on the renin–angiotensin system (C09)ACE inhibitors("-pril")
Sulfhydryl-containing: Captopril
Rentiapril
Zofenopril
Dicarboxylate-containing: Enalapril#
Benazepril
Cilazapril
Delapril
Imidapril
Lisinopril (+amlodipine, +HCT)
Moexipril
Perindopril (+indapamide)
Quinapril (+HCT)
Ramipril
Spirapril
Temocapril
Trandolapril
Phosphonate-containing: Ceronapril
Fosinopril (+HCT)
Other/ungrouped: Alacepril
AIIRAs("-sartan")
Azilsartan
Candesartan
Eprosartan
Fimasartan
Irbesartan (+HCT)
Losartan (+HCT)
Olmesartan (+amlodipine, +amlodipine and HCT)
Tasosartan§
Telmisartan (+amlodipine, +HCT)
Valsartan (+amlodipine, +amlodipine and HCT, +HCT)
Renin inhibitors("-kiren")
Aliskiren (+amlodipine, +HCT, +amlodipine and HCT)
Remikiren§
Dual ACE/NEP inhibitors
Gemopatrilat
Ilepatril
Omapatrilat
Sampatrilat
Neprilysin inhibitors
Sacubitril (+valsartan)

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteAngiotensin receptor modulatorsATR
Agonists: Angiotensin II
Angiotensin III
Angiotensin IV
L-163,491
Saralasin
Antagonists: Abitesartan
Azilsartan
Candesartan
Elisartan
Embusartan
Eprosartan
EXP-3174
Fimasartan
Forasartan
Irbesartan
Losartan
Milfasartan
Olmesartan
Olodanrigan
PD123319
Pomisartan
Pratosartan
Ripisartan
Saprisartan
Sparsentan
Tasosartan
Telmisartan
Valsartan
Zolasartan
ACE inhibitors: Alacepril
Benazepril
Captopril
Cilazapril
Delapril
Enalapril
Enalaprilat
Fosinopril
Gemopatrilat
Imidapril
Lisinopril
Moexipril
Omapatrilat
Perindopril
Quinapril
Quinaprilat
Ramipril
Rentiapril
Rescinnamine
Spirapril
Spiraprilat
Temocapril
Trandolapril
Zofenopril
Zofenoprilat
Renin inhibitors: Aliskiren
Ciprokiren
Ditekiren
Enalkiren
Imarikiren
Pepstatin
Remikiren
Terlakiren
Zankiren
Propeptides: Angiotensinogen
Angiotensin I
Combinations:
Amlodipine/valsartan
Olmesartan/amlodipine
Olmesartan/amlodipine/hydrochlorothiazide
Valsartan/hydrochlorothiazide
Valsartan/hydrochlorothiazide/amlodipine

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





